fda warning letters compounded semaglutide october 2025 glp-1 enforcement news issued 25 to telehealth companies for false Beyond the Headlines: FDA Warning

Function: It is a solvent/diluent only and contains no active therapeutic agents itself.

Sustained treatment with semaglutide leads to a reduction of blood pressure by 1.8 to 4.6 mm Hg compared with other glucose-lowering agents or placebo [82, 83]

The remainder of this analysis will review the law and risks related to this decision

Notably, the improvements in blood pressure were substantial enough to result in the discontinuation of at least one antihypertensive medication in a notable proportion of retatrutide-treated participants, further highlighting the drugs potential to mitigate obesity-related cardiovascular complications

K.BaumgartnerJ